Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  New England Journal of Medicine

• Publication date

  1999-06-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJM199906243402504PMID 10379019
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Molecular cytogenetic delineation of 17q translocation breakpoints in neuroblastoma cell lines

  1998cited by this paper
• Stage 4S neuroblastoma: what makes it special?

  1998cited by this paper
• Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience--a pediatric oncology group study.

  1998cited by this paper
• Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization

  1998influential reference
• Sensitive and reliable detection of genomic imbalances in human neuroblastomas using comparative genomic hybridisation analysis.

  1997influential reference
• Promiscuous translocations of chromosome arm 17q in human neuroblastomas

  1997influential reference
• Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization.

  1997cited by this paper
• Biology and genetics of human neuroblastomas.

  1997cited by this paper
• Comparative genomic hybridization study of primary neuroblastoma tumors

  1997cited by this paper
• COMPARATIVE GENOMIC HYBRIDIZATION (CGH) ANALYSIS OF NEUROBLASTOMAS—AN IMPORTANT METHODOLOGICAL APPROACH IN PAEDIATRIC TUMOUR PATHOLOGY

  1997cited by this paper
• Gain of chromosome arm 17q predicts unfavourable outcome in neuroblastoma patients. U.K. Children's Cancer Study Group and the U.K. Cancer Cytogenetics Group.

  1997cited by this paper
• Additional copies of a 25 Mb chromosomal region originating from 17q23.1‐17qter are present in 90% of high‐grade neuroblastomas

  1996influential reference
• Role of ploidy, chromosome 1p, and Schwann cells in the maturation of neuroblastoma.

  1996cited by this paper
• Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma.

  1996cited by this paper
• Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma.

  1995cited by this paper
• 1;17 translocations and other chromosome 17 rearrangements in human primary neuroblastoma tumors and cell lines.

  1994cited by this paper
• Translocation involving 1p and 17q is a recurrent genetic alteration of human neuroblastoma cells.

  1994cited by this paper
• I;17 translocations and other chromosome 17 rearrangements in human primary neuroblastoma tumors and cell lines

  1994cited by this paper
• Fluorescence in situ hybridization combined with immunohistochemistry for highly sensitive detection of chromosome 1 aberrations in neuroblastoma.

  1993cited by this paper
• Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment.

  1993cited by this paper
• Detection of complete and partial chromosome gains and losses by comparative genomic in situ hybridization

  1993cited by this paper
• Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma.

  1993cited by this paper
• Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

  1993cited by this paper
• Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors.

  1992influential reference
• PCR assay for chromosome 1p deletion in small neuroblastoma samples

  1992cited by this paper
• A population-based study of neuroblastoma incidence, survival, and mortality in North America.

  1992cited by this paper
• Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas.

  1985cited by this paper
• Human neuroblastomas and abnormalities of chromosomes 1 and 17.

  1984cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Lactylation-related gene signature as a prognostic biomarker for neuroblastoma: insights into tumor progression and immune modulation.

  2026cites this paper
• Gain of chromosome 17 is an early genetic abnormality in neuroblastoma with PPM1D emerging as a strong candidate oncogene driving tumor progression.

  2025cites this paper
• MYCN as an oncogene in pediatric brain tumors

  2025cites this paper
• Clonal evolution and therapy resistance in the era of precision cancer medicine Evolutionary trajectories in pediatric cancer.

  2025cites this paper
• IGF2BP1 fosters an immunosuppressive tumor microenvironment in high-risk neuroblastoma, contributing to their resistance to immunotherapy

  2025cites this paper
• The PLK4 inhibitor RP-1664 demonstrates potent single-agent efficacy in neuroblastoma models through a dual mechanism of sensitivity

  2025cites this paper
• Tracing metastatic spread in pediatric solid tumors using copy number and targeted deep sequencing

  2025cites this paper
• Prognostic Value of Molecular Aberrations in Low- or Intermediate-Risk Neuroblastomas: A Systematic Review

  2024cites this paper
• Metabolic reprogramming of cancer cells by JMJD6-mediated pre-mRNA splicing associated with therapeutic response to splicing inhibitor

  2024cites this paper
• Extracellular vesicles in neuroblastoma: role in progression, resistance to therapy and diagnostics

  2024cites this paper
• A human neural crest model reveals the developmental impact of neuroblastoma-associated chromosomal aberrations

  2024cites this paper
• Metachronous Bilateral Adrenal Neuroblastoma: A Case Report and Literature Review.

  2024cites this paper
• Epithelial to Mesenchymal Transition in Neuroblastoma: Mechanisms and Therapeutic Considerations

  2024cites this paper
• Early evolutionary branching across spatial domains predisposes to clonal replacement under chemotherapy in neuroblastoma

  2024cites this paper
• Long Non-Coding RNAs in Neuroblastoma: Pathogenesis, Biomarkers and Therapeutic Targets

  2024cites this paper
• DNA Repair and Replicative Stress Addiction in Neuroblastoma

  2024cites this paper
• Patterns of recurrence after radiotherapy for high-risk neuroblastoma: Implications for radiation dose and field.

  2024cites this paper
• Molecular Alterations in Pediatric Solid Tumors.

  2024cites this paper
• FDA Approval Summary: Eflornithine for High-Risk Neuroblastoma Following Prior Multiagent, Multimodality Therapy.

  2024cites this paper
• 17q Gain in Neuroblastoma: A Review of Clinical and Biological Implications

  2024cites this paper
• Defining neuroblastoma: From origin to precision medicine

  2024cites this paper
• Higher tumor mutational burden is associated with inferior outcomes among pediatric patients with neuroblastoma

  2024cites this paper
• The Neuroblastoma Microenvironment, Heterogeneity and Immunotherapeutic Approaches

  2024cites this paper
• Mitochondria-associated gene expression perturbation predicts clinical outcomes and shows potential for targeted therapy in neuroblastoma

  2023cites this paper
• Chromosome 1p status in neuroblastoma correlates with higher expression levels of miRNAs targeting neuronal differentiation pathway

  2023cites this paper
• Inhibition of Survivin Homodimerization Decreases Neuroblastoma Cell Growth

  2023cites this paper
• ALYREF (Aly/REF export factor): A potential biomarker for predicting cancer occurrence and therapeutic efficacy.

  2023cites this paper
• Clinical value of 18F-FDG PET/CT to predict MYCN gene, chromosome 1p36 and 11q status in pediatric neuroblastoma and ganglioneuroblastoma

  2023cites this paper
• Metabolic reprogramming of cancer cells by JMJD 6-mediated pre-mRNA splicing is associated 1 with therapeutic response to splicing inhibitor 2 3

  2023cites this paper
• Metabolic reprogramming of cancer cells by JMJD6-mediated pre-mRNA splicing is associated with therapeutic response to splicing inhibitor

  2023cites this paper
• Metastasis in neuroblastoma: the MYCN question

  2023cites this paper
• IGF2BP1 induces high-risk neuroblastoma and forms a druggable feedforward loop with MYCN promoting 17q oncogene expression

  2023cites this paper
• Target Genes of c-MYC and MYCN with Prognostic Power in Neuroblastoma Exhibit Different Expressions during Sympathoadrenal Development

  2023cites this paper
• IGF2BP1 regulates the cargo of extracellular vesicles and promotes neuroblastoma metastasis

  2023cites this paper
• Prognostic and predictive biomarkers in paediatric solid tumours.

  2023cites this paper
• IGF2BP1 induces neuroblastoma via a druggable feedforward loop with MYCN promoting 17q oncogene expression

  2023cites this paper
• Neuroblastoma of the lumbosacral canal in an adult: a case report and literature review

  2023cites this paper
• Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma

  2022influential citation
• NSUN2 gene rs13181449 C>T polymorphism reduces neuroblastoma risk.

  2022cites this paper
• Immune checkpoint molecules in neuroblastoma: A clinical perspective.

  2022cites this paper
• Single-cell landscape analysis reveals distinct regression trajectories and novel prognostic biomarkers in primary neuroblastoma

  2022cites this paper
• SMARCE1 promotes neuroblastoma tumorigenesis through assisting MYCN-mediated transcriptional activation

  2022cites this paper
• Remarkable Synergy When Combining EZH2 Inhibitors with YM155 Is H3K27me3-Independent

  2022cites this paper
• Neuroblastic tumors and neurofibromatosis type 1: A retrospective multicenter study in Italy and systematic review of the literature

  2022cites this paper
• A Survey on Publicly Available Open Datasets Derived From Electronic Health Records (EHRs) of Patients with Neuroblastoma

  2022cites this paper
• Targeting lipid metabolism in cancer: neuroblastoma

  2022cites this paper
• Connecting telomere maintenance and regulation to the developmental origin and differentiation states of neuroblastoma tumor cells

  2022cites this paper
• Chromosome instability in neuroblastoma: A pathway to aggressive disease

  2022cites this paper
• The Scaffold Protein p140Cap as a Molecular Hub for Limiting Cancer Progression: A New Paradigm in Neuroblastoma

  2021cites this paper
• Neuroblastoma—Telomere maintenance, deregulated signaling transduction and beyond

  2021cites this paper
• Inhibition of the mRNA-Binding Protein IGF2BP1 Suppresses Proliferation and Sensitizes Neuroblastoma Cells to Chemotherapeutic Agents

  2021cites this paper
• Biomarkers in Neuroblastoma: An Insight into Their Potential Diagnostic and Prognostic Utilities

  2021cites this paper
• MEIS2 Is an Adrenergic Core Regulatory Transcription Factor Involved in Early Initiation of TH-MYCN-Driven Neuroblastoma Formation

  2021cites this paper
• Interpretable models for high-risk neuroblastoma stratification with multi-cohort copy number profiles

  2021cites this paper
• An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability

  2021cites this paper
• Molecular Genetics in Neuroblastoma Prognosis

  2021cites this paper
• Evolution of karyotype landscapes in cancer

  2021cites this paper
• Retrospective Analysis of INRG Clinical and Genomic Factors for 605 Neuroblastomas in Japan: A Report from the Japan Children’s Cancer Group Neuroblastoma Committee (JCCG-JNBSG)

  2021cites this paper
• The Erlang distribution approximates the age distribution of incidence of childhood and young adulthood cancers

  2021cites this paper
• How Do Telomere Abnormalities Regulate the Biology of Neuroblastoma?

  2021cites this paper
• Targeting RAS in neuroblastoma: Is it possible?

  2021cites this paper
• Neuroblastoma: the association of anatomical tumour site, molecular biology and patient outcomes

  2021cites this paper
• Molecular Alterations in Pediatric Solid Tumors.

  2021cites this paper
• GAS7 Deficiency Promotes Metastasis in MYCN-Driven Neuroblastoma

  2021cites this paper
• An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability

  2021cites this paper
• Automated Detection of Arm-level Alterations for Individual Cancer Patients in the clinical setting.

  2021cites this paper
• PPM1D Is a Therapeutic Target in Childhood Neural Tumors

  2021cites this paper
• Neuroblastom

  2021cites this paper
• From DNA Copy Number Gains and Tumor Dependencies to Novel Therapeutic Targets for High-Risk Neuroblastoma

  2021cites this paper
• Opportunity knocks for uncovering the new function of an understudied nucleosome remodeling complex member, the bromodomain PHD finger transcription factor, BPTF.

  2021cites this paper
• Molecular and genetic studies in high-risk neuroblastoma

  2021cites this paper
• Etiopathogenesis, symptoms, diagnosis and treatment of neuroblastoma

  2021cites this paper
• Genetics of Pediatric Tumors

  2021cites this paper
• ATR inhibition enables complete tumour regression in ALK-driven NB mouse models

  2021cites this paper
• Comparison of Next-Generation Sequencing and Fluorescence In Situ Hybridization for Detection of Segmental Chromosomal Aberrations in Neuroblastoma

  2021cites this paper
• Mediastinal neuroblastoma, ganglioneuroblastoma, and ganglioneuroma: Pathology review and diagnostic approach.

  2021cites this paper
• Engineering large-scale chromosomal deletions by CRISPR-Cas9

  2021cites this paper
• Targeting Oncogenic Transcriptional Networks in Neuroblastoma: From N-Myc to Epigenetic Drugs

  2021cites this paper
• NTRK1/TrkA Activation Overrides the G2/M-Checkpoint upon Irradiation

  2021cites this paper
• Exploring novel therapeutic strategies in neuroblastoma

  2020cites this paper
• Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group

  2020cites this paper
• Neuroblastoma

  2020cites this paper
• Identification of a minimal region of loss on chromosome 6q27 associated with poor survival of high-risk neuroblastoma patients

  2020cites this paper
• Circulating cell-free tumor DNA analysis in pediatric cancers.

  2020cites this paper
• Extensive Clonal Branching Shapes the Evolutionary History of High-Risk Pediatric Cancers

  2020cites this paper
• New targeted therapies for malignant neural tumors From systematic discovery to zebrafish models

  2020cites this paper
• PPM1D is a neuroblastoma oncogene and therapeutic target in childhood neural tumors

  2020cites this paper
• Distribution of segmental chromosomal alterations in neuroblastoma

  2020cites this paper
• Pathology of Peripheral Neuroblastic Tumors

  2020cites this paper
• The Potential Functional Roles of NME1 Histidine Kinase Activity in Neuroblastoma Pathogenesis

  2020cites this paper
• ijms-648549 2nd Revision by Ugo Rovigatti

  2020cites this paper
• Recurrent chromosomal imbalances provide selective advantage to human embryonic stem cells under enhanced replicative stress conditions

  2020cites this paper
• Nervous system: Embryonal tumors: Neuroblastoma.

  2020cites this paper
• Targeting the DNA Damage Response for the Treatment of High Risk Neuroblastoma

  2020cites this paper
• Evolving treatments in high-risk neuroblastoma

  2020cites this paper
• Tailoring Therapy for Children With Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future.

  2020cites this paper
• Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations

  2020cites this paper
• The p140Cap adaptor protein as a molecular hub to block cancer aggressiveness

  2020cites this paper
• Clinical Significance of Segmental Chromosomal Aberrations in Patients with Neuroblastoma: First Report in Korean Population

  2020cites this paper
• The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project

  2020cites this paper